Show simple item record

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study

dc.rights.licenseopenen_US
dc.contributor.authorBOMMIER, C.
dc.contributor.authorDONZEL, M.
dc.contributor.authorROSSI, C.
dc.contributor.authorFORNECKER, L. M.
dc.contributor.authorBIJOU, F.
dc.contributor.authorCHAUCHET, A.
dc.contributor.authorLEBRAS, L.
dc.contributor.authorYSABAERT, L.
dc.contributor.authorHAIOUN, C.
dc.contributor.authorBOUABDALLAH, K.
dc.contributor.authorGASTINNE, T.
dc.contributor.authorMORINEAU, N.
dc.contributor.authorAMORIM, S.
dc.contributor.authorJARDIN, F.
dc.contributor.authorABRAHAM, J.
dc.contributor.authorLAMY DE LA CHAPELLE, T.
dc.contributor.authorGRESSIN, R.
dc.contributor.authorFOUILLET, L.
dc.contributor.authorFRUCHART, C.
dc.contributor.authorOLIVIER, G.
dc.contributor.authorMORSCHHAUSER, F.
dc.contributor.authorCHERBLANC, F.
dc.contributor.authorBELOT, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLE GUYADER, Sandra
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMONNEREAU, Alain
dc.contributor.authorGHESQUIERES, H.
dc.contributor.authorTHIEBLEMONT, C.
dc.date.accessioned2024-12-11T15:03:18Z
dc.date.available2024-12-11T15:03:18Z
dc.date.issued2024-11-01
dc.identifier.issn1099-1069en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203851
dc.description.abstractEnMarginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real-world data (RWD) evidence in MZL. Real-world data in Lymphoma and survival in Adults (REALYSA) is a prospective multicentric French cohort of newly diagnosed lymphoma patients. This study consists of the first abstraction of MZL patients prospectively included in REALYSA between 12/2018 and 01/2021 with at least 1 year of follow-up. It provides a landscape description of clinical characteristics, initial workup, quality of life and first-line therapy performed in routine practice. Among 207 included patients, 122 presented with EMZL, 51 with SMZL and 34 with NMZL. At baseline, median age was 67 years (range 28-96), and patients reported a favorable global health status (75/100 (IQR 58,83)) - which was higher in NMZL and lower in SMZL patients (p = 0.006). 18FDG-PET/CT was frequently performed at initial workup (EMZL 72%, SMZL 73%, NMZL 85%). Active surveillance was the initial management for 58 (28%) patients. The most prescribed therapies were rituximab-chlorambucil in the EMZL population (30%), rituximab monotherapy in the SMZL population (37%) and R-CHOP (24%)/bendamustine-rituximab (15%) in the NMZL population. At end of first line, overall response rate was 93% among treated patients with 75% of complete response. This French nationwide study provided for the first time prospective RWD on clinical characteristics, initial management and treatment response of MZL patients.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enEpidemiology
dc.subject.enLymphoma
dc.subject.enMarginal Zone Lymphoma
dc.subject.enReal‐World Data
dc.subject.enReal‐World Evidence
dc.title.enReal-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study
dc.title.alternativeHematol Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/hon.3314en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39351974en_US
bordeaux.journalHematological Oncologyen_US
bordeaux.pagee3314en_US
bordeaux.volume42en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Hematological%20Oncology&rft.date=2024-11-01&rft.volume=42&rft.issue=6&rft.spage=e3314&rft.epage=e3314&rft.eissn=1099-1069&rft.issn=1099-1069&rft.au=BOMMIER,%20C.&DONZEL,%20M.&ROSSI,%20C.&FORNECKER,%20L.%20M.&BIJOU,%20F.&rft.genre=article


Files in this item

Thumbnail
Name:
BPH_HON_2024_Bommier.pdf
Size:
1.015Mb
Format:
PDF
View/Open
Thumbnail
Name:
license_rdf
Size:
811bytes
Format:
application/rdf+xml
View/Open

This item appears in the following Collection(s)

Show simple item record